Alder BioPharmaceuticals: Azelby out as CEO of Alder BioPharmaceuticals following close of $2B acquisition
Bob Azelby is replaced by Randy Hassler, who according to his LinkedIn profile was the senior vice president of pharmaceutical operations at Alder for nearly five and a half years.
Read full article »
Alder is a biopharmaceutical company that focuses on developing novel therapeutic antibodies for the treatment of migraine.
Read more